Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Kateryna Vilchevska"'
Autor:
Gili Kenet, Beatrice Nolan, Bulent Zulfikar, Bulent Antmen, Peter Kampmann, Tadashi Matsushita, Chur-Woo You, Kateryna Vilchevska, Catherine N. Bag, Azizan Sharif, Flora Peyvandi, Guy Young, Claude Negrier, Christian Sussebach, Fadi Shammas, Shauna Andersson, Baisong Mei, Kaan Kavakli
Publikováno v:
HemaSphere, Vol 7, p e643526e (2023)
Externí odkaz:
https://doaj.org/article/2a45dff57f9c4ff2bedf75d75d9983b0
Publikováno v:
HemaSphere, Vol 7, p e02217c7 (2023)
Externí odkaz:
https://doaj.org/article/79b982cbf1994de98be04889de9b0850
Autor:
Maria Elisa Mancuso, Carmen Altisent, Hervé Chambost, M. Jansen, Anthony K.C. Chan, Mark Belletrutti, Jonathan M. Ducore, Paolo Gresele, John K. Wu, Ri Liesner, Sunil Lohade, Manuela Carvalho, Berardino Pollio, Benoît Guillet, Aby Abraham, Johannes Oldenburg, Sigurd Knaub, Anna Klukowska, Ellis J. Neufeld, Anna Pavlova, Leonid Dubey, Marianne Sigaud, Manuel Carcao, Víctor Jiménez-Yuste, Lidija Kitanovski, Larisa Belyanskaya, Kateryna Vilchevska, Michael Gattens, Olaf Walter, Vladimir Vdovin, Yves Gruel
Publikováno v:
Thrombosis and Haemostasis
Thrombosis and Haemostasis, Schattauer, 2021, ⟨10.1055/s-0040-1722623⟩
Thrombosis and Haemostasis, 2021, 121 (11), pp.1400-1408. ⟨10.1055/s-0040-1722623⟩
Thrombosis and Haemostasis, Schattauer, 2021, ⟨10.1055/s-0040-1722623⟩
Thrombosis and Haemostasis, 2021, 121 (11), pp.1400-1408. ⟨10.1055/s-0040-1722623⟩
Introduction FVIII inhibitor development is the most serious contemporary treatment complication in haemophilia A, particularly in previously untreated patients (PUPs). No inhibitors developed in clinical trials in previously treated patients treated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8796168da5f744cf29cd3b770616d144
https://hal.archives-ouvertes.fr/hal-03162369/document
https://hal.archives-ouvertes.fr/hal-03162369/document
Autor:
Vadim A Doronin, Huaibao Feng, Thierry Facon, Natalia Domnikova, Karthik Venkatakrishnan, Maryna Y. Kyselyova, Donna Skee, Ievgenii Karamanesht, Kateryna Vilchevska, Suzette Girgis, Helgi van de Velde, Alexander Schmidt, Dixie-Lee Esseltine, Cyrille Hulin, Xavier Leleu, Andrew Cakana, Philippe Moreau, William Deraedt
Publikováno v:
Clinical pharmacokinetics. 51(12)
The proteasome inhibitor bortezomib is approved for the treatment of multiple myeloma (MM) and, in the US, for the treatment of mantle cell lymphoma following at least one prior therapy; the recommended dose and schedule is 1.3 mg/m(2) on days 1, 4,
Autor:
Emanuil Gheorghita, Kate Talks, Isidro Jarque, Mario von Depka Prondzinski, Gloria Pérez Rus, Jerzy Windyga, Prasad Sripada, Javier Loscertales, Mimi F Flensburg, Peter S. Andersen, Mihaela Lazaroiu, T. P. R. Bharadwaj, Dina Attias, Henrik Næsted, Jørgen Petersen, Andrei Cucuianu, Tadeusz Robak, Kateryna Vilchevska, Jacek Treliński, Kazimierz Kuliczkowski, Dusica Celeketic, Niels Jorgen Ostergaard Skartved, Andrzej Hellmann, Ofer Shpilberg, Ann Janssens, María Teresa Álvarez-Román, Kalinina Svetlana, Wiesław Wiktor Jędrzejczak, Chantal Doyen, Mukhyaprana Prabhu, Aristoteles Giagounidis, Nichola Cooper, Torben P. Frandsen, Elena Karyagina, Lana M. Golubovic
Publikováno v:
Blood
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Rozrolimupab, a recombinant mixture of 25 fully human RhD-specific monoclonal antibodies, represents a new class of recombinant human antibody mixtures. In a phase 1 or 2 dose escalation study, RhD+ patients (61 subjects) with primary immune thromboc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6ea1c09cb786974514c7884ed079d6c
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1271
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1271
Autor:
Karthik Venkatakrishnan, Huaibao Feng, Natalia Domnikova, Cyrille Hulin, Kateryna Vilchevska, Maryna Y. Kyselyova, Alexander Schmidt, Suzette Girgis, Dixie-Lee Esseltine, Thierry Facon, William Deraedt, Vadim A Doronin, Donna Skee, Ievgenii Karamanesht, Philippe Moreau, Xavier Leleu, Andrew Cakana
Publikováno v:
Blood. 118:1863-1863
Abstract 1863 Background: The proteasome inhibitor bortezomib is approved for the treatment of multiple myeloma (MM); the recommended dose and schedule is 1.3 mg/m2 administered by intravenous (IV) injection on days 1, 4, 8, and 11 of 21-day cycles.